Edgewise Therapeutics (EWTX) Non-Current Assets (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Non-Current Assets data on file, last reported at $8.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 22.14% year-over-year to $8.7 million; the trailing twelve-month figure through Mar 2026 stood at $37.6 million (down 19.33% YoY), and the FY2025 full-year result was $9.2 million, down 18.67% from the prior year.
• Non-Current Assets declined to $8.7 million in Q1 2026, from $9.2 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $13.6 million in Q2 2023 to a low of $4.1 million in Q2 2022.
• A 5-year average of $10.3 million and a median of $11.2 million in 2025 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets surged 674.05% in 2022 and slipped 22.14% in 2026, its largest moves.
• Tracing EWTX's Non-Current Assets over 5 years: stood at $10.1 million in 2022, then rose by 29.06% to $13.0 million in 2023, then dropped by 13.07% to $11.3 million in 2024, then slipped by 18.67% to $9.2 million in 2025, then decreased by 5.29% to $8.7 million in 2026.
• Business Quant data shows EWTX's Non-Current Assets at $8.7 million in Q1 2026, $9.2 million in Q4 2025, and $9.6 million in Q3 2025.